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Abstract
The treatment of cartilage defects poses a clinical challenge owing to the lack of intrinsic regenerative
capacity of cartilage. The use of tissue engineering techniques to bioengineer articular cartilage is
promising and may hold the key to the successful regeneration of cartilage tissue. Natural and synthetic
biomaterials have been used to recreate the microarchitecture of articular cartilage through multilayered
biomimetic scaffolds. Acellular scaffolds preserve the microarchitecture of articular cartilage through a
process of decellularization of biological tissue. Although promising, this technique often results in poor
biomechanical strength of the graft. However, biomechanical strength could be improved if biomaterials
could be incorporated back into the decellularized tissue to overcome this limitation.
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Summary
The treatment of cartilage defects poses a clinical challenge due to the lack of intrinsic regenerative
capacity of cartilage. The use of tissue engineering techniques to bioengineer articular cartilage is
promising and may hold the key to the successful regeneration of cartilage tissue. Natural and
synthetic biomaterials have been used to recreate the microarchitecture of articular cartilage
through multilayered biomimetic scaffolds. Acellular scaffolds preserve the microarchitecture of
articular cartilage through a process of decellularisation of biological tissue. Although promising, this
technique often results in poor biomechanical strength of the graft. Biomechanical strength could be
improved however, if biomaterials could be incorporated back into the decellularised tissue to
overcome this limitation.

Word count: 4437 (excluding summary, tables, figures, references)
Keywords: Bioengineering, Cartilage, Regeneration, Defects, Review, Tissue Scaffolds, Stem Cells
Background
Cartilage damage can result in pain and loss of function for many patients, and the
management of moderate to severe defects has been difficult due to the lack of intrinsic capacity for
cartilage to regenerate [1,2]. The fibrocartilage formed differs substantially from hyaline cartilage;
therefore the goal is to form regenerative tissue with compressive and hydrodynamic qualities
similar to hyaline cartilage. Many reports relate compromised function associated with repaired
cartilage and loss of function of the articular surface [3].
Traditional methods of repair of osteochondral defects include debridement, marrow
stimulation, osteochondral grafting and autologous chondrocyte implantation (ACI) [4-9].
Arthroscopic debridement and lavage provides symptomatic relief but does not change the natural
course of the disease and has similar outcomes to placebo surgery [10,11]. Marrow stimulation,
usually in the form of microfracture, relies on local recruitment of marrow based stem cells and
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growth factors to the site of articular repair [12]. The resulting fibrocartilaginous repair does not
resemble surrounding hyaline cartilage, consisting of less collagen type II [13]. A prospective study
on microfracture showed good to excellent in 67% of patients following a mean postoperative
follow-up period of 3.6 years [14]. However, results of microfracture deteriorate over time due to
the formation of fibrocartilage in the repair tissue [15,16].
Osteochondral grafting and ACI techniques however aim to regenerate hyaline cartilage.
Recent 10 year follow-up study showed superior clinical results of osteochondral grafting compared
with microfracture in young athletes with focal osteochondral defects [17]. An earlier clinical study
of ACI showed an improvement in symptoms in 14 out of 16 patients at 2 years who had femoral
condylar lesions [18]. Peterson et al showed good to excellent clinical results following ACI in a 2- to
9-year followup period, in particular in patients with isolated femoral condyle lesions and
osteochondritis dissecans of the knee [19]. At 10 to 20 years post ACI implantation, 74% of 224
patients reported improvements in symptoms [20]. Similarly, Vijayan et al recently reported 12 out
of 14 patients with good to excellent clinical outcomes at 2 to 8 year followup (average 5.2 years)
post matrix-induced autologous chondrocyte implantation (MACI) [21]. However in a 5 year long
term randomised controlled trial, ACI results have been comparable to microfracture, although
subgroup analysis of that trial showed patients with onset of symptoms less than 3 years had better
outcome with chondrocyte implantation than microfracture [22].
Disadvantages of osteochondral grafting include limitations on donor site availability and
morbidity [23]. The space between cylindrical grafts may impair the quality of the repair as Lane et al.
found poor integration of full thickness gaps in experiments in goats [24]. ACI is technically
challenging with high reoperation rates of 9-20% and associated higher costs [14]. In one study, 36%
of periosteal patches required debridement of the graft due to periosteal hypertrophy [25]. It also
requires ex vivo expansion of chondrocytes which necessitates two operations typically at an interval
of 2 weeks.
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New products have since been introduced for clinical trials and clinical use. These products
are based on traditional methods of repair, enhanced with tissue engineering techniques, and are
summarised in table 1. Although a few have shown some promise, the majority lack long term
studies and complications have been reported [26,27].
Although techniques such as osteochondral grafting and ACI have shown improvements over
microfracture in certain cases, further improvements can be made to increase the longevity and
consistency of clinical results achieved through current standards of care. As a result substantial
research continues to focus on advancements in tissue engineering of cartilage to overcome the
limitation of current repair methods and to develop a bioengineered cartilage regeneration therapy.
Biomimetic scaffolds using natural and synthetic biomaterials have attempted to reverse engineer
the complex microarchitecture of hyaline cartilage. Recent developments in acellular biological
scaffolds, which aim to preserve the native microarchitecture of cartilage to aid in regeneration of
cartilage defects, may hold the key and the future of articular cartilage regeneration.

Tissue Engineering
Tissue engineering has the potential to overcome the limitations of current treatment
options for osteochondral defects. Tissue engineering combines the use of cells, biomaterials and
stimulatory factors to regenerate and reconstruct the osteochondral unit. 3D tissue grafts can be
shaped, engineered and tailored to specific needs to improve structural, biological and
biomechanical properties of current repair processes [28].
Cell Source
Chondrocytes, fibroblasts, stem cells and genetically modified cells have been explored as
sources for cartilage regeneration, the goal of which is to identify a source that can be reliably used
to regenerate good quality articular cartilage [2].
Chondrocytes
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Chondrocytes are responsible for the secretion and maintenance of extracellular matrix and
appear to be the logical cell of choice. Mature chondrocytes secrete type 2 collagen and sulphated
glycosaminoglycans (GAGs) as extracellular matrix to maintain and remodel the cartilage matrix [29].
However the use of chondrocytes is limited by two major concerns. Chondrocytes are limited in
number comprising only 2-5% of cartilage tissue and thus require expansion prior to use [29-31].
Furthermore, the process of expansion and cell culture causes dedifferentiation of mature
chondrocytes so synthesis of proteoglycans and collagen Type II is decreased and collagen
expression converts to collagen Type I [32-34]. A variety of methods have been used to prevent or
limit the degree of dedifferentiation such as three dimensional culture and scaffolds, bioreactors,
reduced oxygen tension and addition of growth factors such as transforming growth factor β (TGF-β),
FGF and insulin like growth factor (IGF) [35-40]. These methods have produced hyaline cartilage,
with varied success, in in-vitro studies.
Stem Cells
To avoid the limitations of chondrocytes, mesenchymal stem cells (MSCs) have been used
for chondrogenesis and osteogenesis [41]. MSCs are found in a variety of human tissue including
bone marrow, periosteum, synovial membrane, skeletal muscle, dermis, blood and adipose tissue
[40,42-44]. Bone marrow-derived stem cells (BMSCs) have been most extensively studied. However,
BMSCs have been shown to express markers showing hypertrophic chondrogenesis (type X collagen
and MMP-13) that mineralize when exposed to osteogenic stimuli [45-47]. Adipose-derived stem
cells (ADSCs) are commonly used for the generation of chondrocytes due to their ease of harvest
and the availability of larger numbers of stem cells [48]. Together with various growth factors such
as TGF-β and scaffold or culture media, such as alginate or agarose gel, these cells have been shown
to undergo chondrogenesis with enhanced production of collagen Type II and aggrecan [49-54].
However, MSCs tend to produce inferior matrix in terms of mechanical integrity compared with
chondrocytes [55].
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Human embryonic stem cells (hESCs) represent an alternative cell source for chondrogenesis
due to their vast differentiation capacity into various somatic cell lineages and proliferative
capabilities. A recent study demonstrates the ability for hESCs to undergo efficient chondrogenic
differentiation using a hyaluronic acid hydrogel method of delivery in a rat model. They also showed
complete integration of the hESCs engineered cartilage with surrounding cartilage in two-thirds of
animals without the development of tumours at 12 weeks [56]. Hwang et al showed that
mesenchymal stem cells derived from hESCs, are capable of multilineage differentiation into fat,
cartilage and bone in vitro, and achieving normal cartilage architecture in rat osteochondral defect
repair [57].
Recently, induced pluripotent stem cells (iPSCs) have been used to different both osteogenic
and chondrogenic cell types [58,59]. Like hESCs, iPSCs has the potential to provide great scope for
cellular expansion and differentiation compared to mesenchymal stem cells, without the same
ethical problems [60]. There is always a risk of tumourigenicity associated with the use of stem cells
and in particular the use of viral vectors. Newer methods that generate iPSCs without viral vectors
have been developed to reduce the risk of tumourigenicity [61-64]. Overall chondrogenic
differentiation of iPSCs is still in its formative stages of development and further work is required to
evaluate its full potential in the field of osteochondral regeneration.
Scaffolds
Scaffolds provide the environment into which cells can grow and produce cartilage tissue
and extracellular matrix. As related above, chondrocytes require 3D culture to avoid
dedifferentiation of their phenotype [65]. Furthermore, the process of dedifferentiation can be
reversed when chondrocytes are relocated into a three-dimensional (3D) environment [66-68].
Scaffolds can be made from a diverse range of materials including natural or synthetic materials or a
hybrid of both. They can also be designed in forms of hydrogels, sponges, or fibrous mesh. Hydrogels
support the transportation of cells and bioactive agents and can suspend cells in a three dimensional
6

environment. They can also be injected to fill defects of any size and shape. However they have
inferior mechanical properties compared with other forms of scaffolds [69]. Sponges are porous
scaffolds that facilitate cell adhesion. Pore size variation affects cell adhesion, migration and
deposition [70]. Meshes can also be made to variable porosities governed by fibre diameter and
direction. They exhibit greater mechanical strength but irregular filling into the mesh itself may
compromise the quality of the graft and affect tissue integration. 3D constructs of woven fibres and
electrospinning have been used to mimic the native cartilage material and 3D environment [71,72].
Natural materials
Natural materials used in cartilage engineering include collagen, hyaluronic acid (HA),
chitosan, alginate, fibrin, silk, gelatin, bacterial cellulose, and cartilage derived matrix. Examples of
these materials are summarised in table 2 along with their respective advantages and disadvantages.
Collagen and hyaluronic acid are two of the most common materials used in cartilage engineering
and clinically most relevant, with many products already in clinical use and trial which are based on
tissue engineered collagen or hyaluronic acid materials. Thus, these materials will be discussed
further.
Collagen has the advantage of being biodegradable, biocompatible and ability to be
crosslinked [73]. Therefore it is a versatile materials used in tissue engineering. Collagen can be
formed into different types of scaffolds including sponges, membranes, films, gels and fibres using a
variety of fabrication methods [74]. Each fabrication method produces a different set of mechanical
and biochemical properties. Methods that induce pore formation such as freeze-drying process
result in greater porosity which allows greater cellular and soluble factor infiltration into the
materials whilst decreases the inherent biomechanical strength of the material [75]. Collagen
hydrogels are easy to make and forms a gel that can absorb large amounts of fluid which aids in
cellular infiltration. However in the gel form collagen fibres are not aligned and therefore do not aid
in manipulation of the microarchitecture of the material to mimic the natural environment [76].
7

However, in some cases the use of collagen has resulted in a foreign body reaction and poor
integration with surrounding tissue [2,77].
Recently, a two year randomised clinical trial of NeoCart, a collagen type I based bioscaffold
seeded with autologous chondrocytes cultured in a bioreactor, showed improved clinical outcomes
compared with baseline and microfracture groups [78]. Adverse events related to the study were
consistent with those associated with knee arthroscopy. Whilst the results are promising, larger
studies over longer periods are required before definitive conclusions can be drawn on the efficacy,
safety and benefit of novel therapies.
Hyaluronan is an important component of the extracellular matrix of cartilage. Not only does
it hold water to give compressive strength to cartilage, it also interacts with binding proteins,
proteoglycans and growth factors which help maintain the ECM structure [79]. Hyaluronic acid (HA)
is useful in the development of hydrogels due to its negative charge and water-trapping properties
[80]. HA has been used extensively in tissue engineering not only for bone and cartilage but also in
liver, cardiac, vascular, dermal, ophthalmic and neural tissue [81]. Mechanical, degradation rates and
biological function can often be modified and controlled through modification of the HA molecule
via chemical derivatisation and/or crosslinking with different molecules [82,83]. Toh et al found that
lower cross-linking improved chondrogenesis of mesenchymal stem cells in a HA based hydrogel
with increases in the percentage of cells with chondrocytic morphology and improved biosynthesis
of collagen type II and glycosaminoglycans. Increasing hydrogel cross-linking improved matrix
stiffness but promoted fibrocartilage formation [84]. HA also exists as fibrous scaffolds in the form of
Hyaff. Hyaff scaffolds have been shown to allow growth of chondrocytes and support the
chondrogenic and osteogenic differentiation of mesenchymal stem cells [85,86]. Hyalograft C
autograft is composed of autologous chondrocytes grown in a 3D Hyaff scaffold, and was first
introduced into the clinical setting in 1999 for the repair of full thickness cartilage defects [79].
Recent prospective clinical case series, with 2 and 7 year follow-up, showed clinical improvement in
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young patients with single defects, however for patients with more advanced disease or with
generalised osteoarthritis the results were poor [87].
Synthetic polymers
Synthetic biodegradable polymers offer an alternative to natural materials for the purposes
of tissue engineering. These materials offer certain advantages in recreating the complex and
dynamic nature of native ECM. The key advantage include increased mechanical strength,
degradation kinetics, versatility of fabrication methods with excellent control over shape, size and
porosity, as well as the ability to add functional chemical groups to enhance the biological effect of
the material [88]. Biodegradation has proven to be important in clinical use. Biodegradable polymers
such as poly(glycolic acid), poly(lactic acid) and their copolymers have been in clinical use since the
1960s such as in resorbable sutures [89]. Since then many other materials such as poly(dioxanone),
poly(trimethylene carbonate) copolymers, and poly(ε-caprolactone) have been used in many
medical devices [90,91]. The ideal polymer must consist of the appropriate mechanical properties to
match the native ECM whilst allowing sufficient degradation time for tissue healing or regeneration
to occur. However it must not cause inflammation or toxicity from the material itself or its
degradation products and ideally be fully metabolized by the body after use [89]. A number of
materials have been used for cartilage tissue engineering listed in Table 2.
Poly(α-hydroxy esters) include poly(lactic acid) (PLA), poly(glycolic acid) (PGA), the
copolymer poly(lactic-co-glycolic acid) (PLGA), and poly(ε-caprolactone) [92]. They are the most
commonly used synthetic biodegradable polymers for cartilage tissue engineering [93]. PLA exists in
three isomer forms: poly(L-lactic acid), poly(D-lactic acid), and poly(DL-lactic acid) depending on the
position of the methyl group [92]. Amongst these poly(L-lactic acid) and poly(DL-lactic acid) are used
more often as biomaterials. Poly(L-lactic acid) is a semicrystalline polymer exhibiting high tensile
strength and low elongation making it suitable for load bearing applications such as sutures and
orthopaedic fixation devices [94,95]. Poly(DL-lactic acid) is an amorphous polymer consisting of a
9

random distribution of each isomer and therefore has lower tensile strength and higher elongation
and more rapid degradation, therefore making it more useful in a drug delivery system [89].
PGA is a highly crystalline polymer with high tensile strength used to develop the synthetic
absorbable suture known as DEXON® in the 1970 [96]. However PGA also exhibits a high degradation
rate and low solubility in most organic compounds due to its highly crystalline structure. This can
result in the accumulation of degradation products which can cause inflammatory reactions [97,98].
One major issue with the use of synthetic materials is the acidic degradation by-product of
the polyester materials. This has been implication in the stimulation of inflammatory reactions as
well as deactivation of proteins in the surrounding tissue [99]. Therefore, this has led to the
development of copolymers of the lactides/glycolides with other monomers to form poly(ether
esters), poly(ester carbonates), poly(ester amides) and poly(ester urethanes) [100-105].
Shi et al (2012) used a 3D fibrous poly(L-lactic-co-glycolic acid) (PLLGA) scaffold to repair
femoral trochlear lesions in rabbit knees. They showed when combined with microfracture the
repair of full thickness defects was more rapid and efficient when compared to either microfracture
or scaffold alone. There was positive staining of collagen type II and toluidine blue with good
integration of repair tissue at 24 weeks [106]. Tru-Fit Plug (Smith & Nephew, Andover, MA, USA) is a
synthetic resorbable biphasic implant from polyactide-coglycolide copolymer, calcium sulphate and
polyglycolide. In early results, it has shown formation of fibrocartilage with inferior biomechanical
stability when subject to high shear forces in the knee, ongoing articular surface irregularity resulting
in subsequent arthritic change and delayed integration [107-109].
Techniques to accelerate chondrogenesis
Stimulating factors modulate cell behaviour and this may be by direct biochemical
interaction or induced by mechanical stimulation. Growth factors commonly used to induce
chondrogenesis of various cell types. Articular cartilage is subjected to mechanical pressure under
physiological conditions. Mechanical stimulation such as hydrostatic pressure and dynamic
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compression techniques have been used to mimic intra-articular conditions and do improve
chondrogenesis in vitro [110,111]. Furthermore, the addition of growth factors with mechanical
stimulation seems to produce synergistic effects [112].
Growth factors
Multiple growth factors play an important role in the chondrogenesis of stem cells. The
transforming growth factor-beta (TGF-β) superfamily contains many which promote chondrogenesis,
including TGF- β1, TGF- β3, BMP-2, BMP-4, BMP-7, and GDF-5 have been shown to promote
cartilaginous ECM production [113]. Whilst they all promote cartilaginous ECM production, TGF- β1
and BMP-2 also down-regulate collagen type I production [114]. Insulin-like growth factor 1 (IGF-1) is
the main anabolic growth factor in cartilage and controls proteoglycan synthesis and breakdown,
and induces expression of chondrocyte phenotype [115]. Its effect is independent to the TGF-β
signalling pathway and therefore when combined leads to additive effects on cartilage matrix
synthesis [116,117]. Fibroblast growth factor (FGF)-2 and FGF-18 promotes the proliferation of
chondrocytes and helps to prevent cartilage against damage [118,119].
Oxygen tension
Articular cartilage is avascular with oxygen and nutrients being delivered via passive
diffusion from synovial fluid [68]. Therefore, articular cartilage exists naturally in a low oxygen
environment. Hypoxia inducible factor (HIF) mediates transcription factors to allow chondrocytes to
adapt to low oxygen tension [120]. Hypoxia has been shown to increase the synthesis of ECM
proteins in vitro in both chondrocytes as well as hypoxia-induced chondrogenic differentiation of
MSCs [67,121,122]. Hypoxia has also been shown to inhibit the expression of collagen Type X,
present in fibrocartilage and a marker of chondrocyte hypertrophy [123,124]. Therefore it seems
hypoxia is an important environmental factor to be considered for cartilage regeneration.
Bioreactor
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Bioreactors are used to improve nutrient transport and provide a fluid-induced shear stress
to tissues to promote chondrogenesis. Current bioreactors used for cartilage tissue engineering
include parallel-plate bioreactors, rotating wall bioreactors, and concentric cylinder bioreactors
[38,125,126]. Lu et al (2012) showed increased deposition of collagen II and glycosaminoglycans
leading to the formation of cartilage like tissue in a rotating-shaft bioreactor using TGF-β3 expressing
adipose stem cells[127].
Electrical stimulation
Electrical stimulation has also been employed to induce cartilage and bone repair. In 1974,
Baker et al. attempted to enhance cartilage repair stimulation of articular cartilage repair by
electrical means using bimetallic devices inserted into full-thickness articular cartilage defects [128].
They demonstrated enhancement of latent potential for repair with hyaline cartilage. The repair
response appeared to derive from proliferating chondrocytes at the defect margin, with
encroachment over the surface of the central defect. More recently Brighton et al. reported that
capacitatively coupled electrical signal resulted in significant up-regulation of cartilage matrix
protein expression and production while simultaneously significantly attenuating the up-regulation
of metalloproteinase expression [129]. These results support the contention that delivery of a
specific, defined electrical field to articular cartilage could result in matrix preservation. They
concluded that the use of electrical stimulation to both increase matrix production and diminish
matrix destruction has the promising potential to treat osteoarthritic patients in a non-invasive
manner.
Recreating the microarchitecture of articular cartilage
The biomechanical function of articular cartilage results from the structure of the
extracellular matrix. The dense network of collagen and proteoglycans in the ECM not only support
chondrocyte attachment but also transmits mechanical force within the ECM to allow cells to
respond to mechanical stress [130]. The collagen network provides tensile strength and the
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proteoglycans, due to their negative charge, maintains high levels of approximately 70% water
content to resist compressive forces [131]. The intrinsic structure of articular cartilage is further
organized into three distinct zones: superficial or tangential, middle or transition, deep or radial zone.
This sits above a layer of calcified cartilage. Each zone has distinct ECM composition, organisation
and cellular phenotype. Towards the superficial layer the chondrocytes are smaller, thinner, and
orientated parallel to the articulating surface along with the orientation of the collagen network to
provide resistance to shear forces [132]. Here chondrocytes also secrete lubricin, otherwise known
as superficial zone protein, which acts to reduce friction resistance of the cartilage [29,133]. The
middle zone consists of larger rounded chondrocytes with random collagen orientation with high
levels of proteoglycans [134]. The deep zone consists of oval chondrocytes with collagen fibres
forming a vertical or perpendicular alignment. Deep zone cells produce more collagen and
proteoglycans than the superficial layer however has a lower cell density [131].
Biomimetic scaffolds
Most attempts to date at bioengineering cartilage have focused on using natural and
synthetic biomaterials, as mentioned previously, to mimic the natural microarchitecture and
biomechanical properties of native cartilage. Recent examples of such an approach include Kon et al,
where a multilayered gradient nano-composite scaffold using collagen type I fibrils with
hydroxyapatite nanoparticles were used in a pilot trial of thirty patients with chondral and
osteochondral knee lesions [135]. Others have used fibre-hydrogel composite materials to mimic the
native extracellular structure [136]. More examples are listed in the references of table 2 and many
have been discussed throughout the course of this review. The advantages and disadvantages of
each scaffold relate to the materials used. However in general composite materials attempt to
harness the strengths of each material used.
Acellular biological scaffolds
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Acellular scaffolds consist of noncellular parts of a tissue such that collagen and
carbohydrate structures are maintained in their natural state. Therefore they should maintain the
appropriate environment for cellular re-attachment, migration, differentiation and proliferation to
enhance tissue regeneration when transplanted, whilst maintaining, in theory, a perfect
microarchitecture for the repair tissue (Figure 1) [137]. In recent years decellularised biological
matrices has been used to regeneration various tissue types including skin, cartilage, bladder, spinal
cord, and myocardium[138-142].
A number of studies to date have described the use of acellular cartilage matrices in the
repair of chondral and osteochondral defects [143,144]. Cheng et al showed acellular porcine
cartilage-derived matrix was able to support the growth of neocartilage formation in the absence of
exogenous growth factors [143]. Recently the same group was able to induce chondrogenic
differentiation of human adipose-derived stem cells without exogenous growth factors on an
acelluar cartilage matrix crosslinked with genipin to prevent scaffold contraction [145].Schwarz et al
have shown the successful decellularisation and sterilization of porcine knee and nasal cartilage and
human nasal cartilage. They also show the ability to remove proteoglycan content whilst maintaining
the collagen structure. However the decellularisation process also increased the amount of
denatured collagen compared with native cartilage. Overall there was significant decrease of
biomechanical loading stress, which the acellular matrix showing reduced stiffness by about 69.5%
[146]. The matrix did however support the growth of chondrocytes and re-acculumation of
proteoglycans in the process of in vitro culture [147]. Kang et al also reported the use of
decellularized cartilage ECM scaffold loaded with adipose stem cells [148]. They used a rabbit
osteochondral defect model to show adipose stem cell loaded ECM scaffold induced cartilage repair
tissue comparable to native cartilage in both mechanical and biochemical properties at 6 months.
Other types of cell-derived matrix (CDM) including fibroblast-derived matrix, preosteoblastderived matrix and chondrocyte-derived matrix have been explored and found to support and
14

enhance the growth of chondrocytes and provide a chondro-inductive microenvironment for redifferentiation of dedifferentiated chondrocytes [149].
The primary concern with decellularised extracellular matrix is the loss of biomechanical
strength and stability during the process of decellularisation. All studies so far have demonstrated a
loss of mechanical strength as a result of reducing or removing certain components of the
extracellular matrix in order to achieve decellularisation.
Lee et al was able to regenerate an entire joint surface of the rabbit proximal humeral joint
using an acellular bioscaffold created from composite poly-ε-caprolactone and hydroxyapatite
infused with TGF-β3. They found TGF-β3 infused scaffolds yielded uniform chondrocyte distribution
across the surface of the bioscaffold and form hyaline-like cartilage expressing collagen type II and
aggrecan. Furthermore complex microarchitecture of cartilage was recreated as exemplified by the
formation of stratified avascular cartilage and vascularised bone [150]. This study indicates that
using acellular scaffolds to provide a suitable environment for endogenous cell recruitment and
differentiation may be a viable alternative.
Conclusion and future perspectives
Injuries to articular cartilage are common, affect people of all ages and cause significant
morbidity. Cartilage tissue has limited capacity for self-repair and regeneration of fibrous cartilage
post injury results in numerous attempts at repair. Current approaches may provide adequate longterm solutions for certain patient groups; however results can often be inconsistent and comparable
to basic techniques such as microfracture. The implementation of tissue engineering techniques to
improve traditional methods has culminated in many products being taken to clinical trials for use in
clinical practice. Early results for some products show some promise; however, results have been
inconsistent and poor histological repair and complications have been reported.
Regeneration-based tissue engineering approaches should provide better management of
articular cartilage defects. However, our complete understanding of the nature of articular cartilage
15

and the processes which govern tissue regeneration are still not completely understood. The optimal
combination of cells, biomaterials and stimulatory factors to mimic the natural articular
environment are yet to be defined.
In our opinion tissue engineering strategies could be improved in the areas of source of cells
as well as the nature of biomaterials. Recently, the use of iPSCs in the regeneration of bone and
cartilage tissue in vitro and in vivo has demonstrated a potential role in regenerative orthopaedic
medicine [58,59]. iPSCs may prove to have a greater capacity for expansion and differentiation.
However, this technology is in its formative stages and requires development to the stage where
iPSCs may be used safely in clinical settings.
We believe that the key to successful regeneration of osteochondral tissue lies with
recreating not only the composition of the extracellular matrix such as collagen type II and
proteoglycans, but more importantly creating the complex nano-structure and microarchitecture of
cartilage tissue itself. Acellular tissue matrix such as acelluar cartilage matrix may provide the best
possible chance of recapitulating the native microarchitecture of hyaline cartilage in a transplantable
form for tissue regeneration. However the process of decellularisation may cause destruction of
microarchitecture resulting in weaker biomechanical strength than expected. This limitation may be
overcome by augmenting decellularised cartilage with, for example, additional collagen content via
nanofabrication techniques to improve biomechanical strength and stability. Such hybrid scaffolds
may benefit from retaining a natural microarchitecture environment whilst improving biomechanical
strength lost during the decellularisation process.
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Executive summary
Background
•

Cartilage damage is a significant clinical problem and management is difficult due to lack of
intrinsic regenerative capacity of cartilage tissue.

•

New products aim to improve existing technique through the use of tissue engineering
strategies.

Tissue Engineering
•

Tissue engineering combines cells, biomaterials and stimulatory factors to regenerate tissue.

•

Cell sources for cartilage tissue engineering include chondrocytes, mesenchymal stem cells,
embryonic stem cells and induced pluripotent stem cells.

•

Many scaffold materials have been used to support chondrogenesis, and these materials
often include the use of natural and/or synthetic materials.

•

The advantages of natural scaffold materials include increased biodegradability,
biocompatibility, however biomechanical strength can be weaker compared with synthetic
materials.

•

Synthetic materials such as poly(lactic acid), poly(glycolic acid), poly(caprolactone) and their
various copolymers provide an alternative to natural scaffold materials, often providing
greater biomechanical strength. However biodegradation and biocompatibility can be an
issue which limits their use.

•

Often hybrid natural and synthetic scaffolds are used to complement the strengths and
weaknesses of each material.
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•

Stimulatory factors for chondrogenesis include growth factors such as TGF-β, FGF, BMP and
IGF, mechanical stimulation, hypoxic environments, bioreactors, and electrical stimulation.

Recreating the microarchitecture of articular cartilage
•

Recreating the microarchitecture of articular cartilage is crucial to achieving normal
biomechanical function of engineered cartilage.

•

Natural and synthetic materials have been manufactured to mimic the microarchitecture of
articular cartilage.

•

Acellular cartilage matrix is a viable alternative to preserving the microarchitecture
environment, thereby creating a scaffold with enhance regenerative capacity

•

The major drawback with acellular cartilage matrix is the loss of biomechanical strength that
exists with the decellularisation process.

Conclusion and future perspectives
•

Supplementing decellularized tissue with natural and/or synthetic materials through the use
of nanofabrication methods could improve the biomechanical properties of decellularized
tissue while maintaining its natural architecture and biocompatibility properties.
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Figure Legends
Figure 1: Acellular cartilage matrix retains the natural microarchitecture thereby maintain the
appropriate environment for cellular re-attachment, migration, differentiation and proliferation to
enhance tissue regeneration when transplanted.
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Tables
Table 1: Products which enhance traditional methods of repair using tissue engineering approaches
Traditional method

Enhancements

Marrow Stimulation Scaffold-guided
(e.g. microfracture)

Product name

Material

Company

BST-CarGel® [151]

Chitosan-glycerol phosphate based hydrogel

Piramal Healthcare, Laval, Quebec,

microfracture

Canada
ChonDux™ [152]

Photopolymerized hydrogel combined with a Biomet, Inc., Warsaw, IN, USA
biological adhesive

Gelrin C [153]

Osteochondral graft Replacement
(e.g. mosaicplasty)

of Salucartilage

Polyethylene glycol diacrylate (PEG-DA) and Regentis Biomaterials, Regentis, Haifa,
denatured fibrinogen hydrogel

Israel

Biodegradable hydrogel implant

Salumedica, Smyna, GA, USA

osteochondral plug [26,27]
with

natural

and Chondromimetic

Multilayer triple co-precipitate of collagen, TiGenix, Leuven, Belgium

synthetic

[154]

biomaterial graft

Tru-Fit Plug [107- Synthetic resorbable biphasic implant from Smith & Nephew, Andover, MA, USA
109]

glycosaminoglycans and calcium phosphate

polylactide-coglycolide

copolymer,

calcium
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sulphate and polyglycolide
to Carticel [155]

Autologous

Changes

chondrocyte

biomaterials used in

implantation (ACI) / scaffold

scaffolds
Chondrogide [156]

Matrix-assisted
chondrocyte

Porcine-derived type I and type II collagen Genzyme Inc, Cambridge, MA, USA

Hyalograft-C [87]

Porcine-derived type I and type II collagen Geistlich

Biomaterials,

Wolhausen,

scaffolds

Switzerland

Hyaluronic acid based scaffold

Fidia Advanced Biopolymers, Abano

implantation (MACI)

Terma,

Italy),

and

Neocart

(Histogenics, Waltham, MA
Use of bioreactor to Neocart [78]
enhance

in

type I collagen matrix

Histogenics, Waltham, MA

vitro

culture
Morselized cartilage

Cartilage Autograft Morselized cartilage

DePuy/Mitek, Raynham, MA

Implantation
System (CAIS) [157]
DeNovo

Natural Morselized cartilage

Zimmer, Inc., Warsaw, IN, USA
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Tissue (NT) [158]

Table 2:
Table 2: Scaffold materials used for tissue engineering of articular cartilage
Material

Advantages

Disadvantages

Example References

Biocompatible

Some cases of poor

[160]; [161]; [162]; [163]; [39];

integration [77]

[164]; [165]; [166]; [167]; [168];

Natural Materials
Collagen

Contains ligands that aid

[169]

in cell adhesion,
migration and
differentiation [159]
Fibrin

Biodegradable

Weak mechanical strength

[171]; [172]; [173]; [174]

[170]
Fibrin glue can be used
to enhance integration

Rapid degradation [170]

of engineered tissue
with native cartilage and
bone
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Alginate

Aids re-differentiation of

Concerns of

de-differentiated

biocompatibility [176]

[177]; [176]

chondrocytes [66]

In vivo injectable options
[175]

Abundant and low cost
Hyaluronan

Hyaluronan hydrogels

Products of biodegradation

can supplement matrices

can induce chondrolysis

with cells and other

[178]

Hyalograft C [79]; [179]; [180]; [181]

biomimetics [81]
Chitosan

Structurally shares some

Limited solubility [183]

characteristics

[184]; [185]; [186]; [187]; [188];
[189]; [182]; [190]

with various GAGs and

Certain cross-linkage can

hyaluronic acid[182]

result in poor
biocompatibility

Degradation products
non-toxic and are
involved in the synthesis
of articular cartilage
- Chondroitin sulphate,
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Dermatan sulphate,
Hyaluronic acid, Keratin
sulphate, Glycosylated
type II collagen
Bacterial Cellulose

Biocompatibility

Lack of direct bond between

[191]

cellulose and bone
Match of mechanical
properties with hard and
soft tissue

Implantable in gel form
Cartilage Derived Matrix

Biocompatibility

Lower mechanical strength

[143]; [144]; [192]

and higher rates of
Support neocartilage

degradation compared with

formation in absence of

synthesized scaffolds

exogenous growth
factors

Chemical cross-linking to
improve strength can cause

Contains entrapped

issues with biocompatibility

bioactive molecules that
interact with cells
Gelatin

Supports growth of

Poor integration with bony

[193]

36

chondrocyte layer in

structures

multilayered scaffold

Uniform porosity allows
better cell growth and
proliferation
Silk

Supports growth of

Issues with biocompatibility

chondrocytes

and allergic reactions with

[194]; [195]

certain types of silk
Good tensile strength
Synthetic Materials
Poly(α-hydroxy esters)

Satisfactory

Degradation by-products

[197];[198]; [199]; [197]; [200];

biocompability [97]

has been shown to elicit

[201]; [202]; [203]; [204]; [205];;

inflammatory response and

[92]; [206]; [207]; [208]; [209];

decreased pH level [98]

[210]; [211]; [212]; [209]; [213]

•

Poly(lactic acid)

•

Poly(glycolic acid)

•

Poly(lactic-co-glycolic)

Good mechanical

•

Poly(caprolactone)

properties
Mechanical stiffness can

Poly(ethylene glycol)

Flexibility in degradation

sometimes be undesirable

rates

[196]

Hydrophilicity

[214]; [215]
Hydrophobicity [196]

Biocompatibility
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Poly(hydroxyalkanoate)

Good biodegradability

Cellular Dedifferentiation

[216]

Poor integration with

[162,217]

Minimal inflammatory
reaction in vivo

Pizoelectric properties
Poly(vinyl alcohol)

Biocompatible

surrounding cartilage
PVA hydrogels have
similar properties to
native cartilage
Poly (urethane urea)

Excellent mechanical and

Polyurethanes using

biochemical properties

polyester diols are

[218]; [219]

hydrolytically unstable
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